Agios Pharmaceuticals (AGIO) shares soared 6.5% in the last trading session to close at $45.22. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 29.9% gain over the past four weeks. The rise in share price is attributable to the company’s progress with its label expansion studies on sol-marketed Pyrukynd. Earlier this month, management reported that the phase III ENERGIZE-T study, evaluating the drug in transfusion-dependent (TD) ...